Parkside Financial Bank & Trust Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Parkside Financial Bank & Trust reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 885 shares of the medical research company’s stock after selling 122 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Thermo Fisher Scientific were worth $470,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Raleigh Capital Management Inc. boosted its holdings in Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares during the period. Cedar Mountain Advisors LLC boosted its holdings in Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 46 shares during the period. Financial Connections Group Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $53,000. Operose Advisors LLC boosted its holdings in Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 75 shares during the period. Finally, Valley National Advisers Inc. boosted its holdings in Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 32 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TMO. The Goldman Sachs Group increased their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Evercore ISI increased their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Royal Bank of Canada increased their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Raymond James increased their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $604.69.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 4.8 %

Shares of NYSE:TMO traded up $26.15 during trading on Tuesday, hitting $574.53. The stock had a trading volume of 1,687,234 shares, compared to its average volume of 1,550,355. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $219.30 billion, a PE ratio of 35.49, a PEG ratio of 2.30 and a beta of 0.80. The firm’s fifty day moving average is $571.30 and its 200 day moving average is $528.18.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter last year, the company earned $5.40 EPS. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.